Table 4. Baseline characteristics and laboratory determinations for patients with dual or triple antiplatelet therapy.
| Variables | Dual therapy, n = 66 | Triple therapy, n = 74 | P value |
| Age (years) | 64.3±10.7 | 62.3±11.3 | 0.284 |
| Male | 50 (75) | 62 (83.8) | 0.198 |
| Risk factors | |||
| Smoking | 28 (41.7) | 42 (57.4) | 0.064 |
| Old myocardial infarction | 16 (23.6) | 21 (27.9) | 0.558 |
| Hypertension | 30 (45.8) | 42 (57.4) | 0.173 |
| Diabetes | 23 (34.7) | 20 (26.5) | 0.29 |
| Kidney disease | 2(2.8) | 1 (1.5) | 0.593 |
| Stroke | 6 (9.7) | 14 (19.1) | 0.112 |
| Peripheral vascular disease | 2 (2.8) | 0 | 0.166 |
| Stent diameter, mm | 2.8±0.9 | 2.9±0.5 | 0.222 |
| Stent length, mm | 62.5±24.6 | 65.1±27.5 | 0.557 |
| Number of stents | 1.8±1.3 | 2.1±1.3 | 0.214 |
| Multivessel disease | 28 (41.7) | 36 (48.5) | 0.415 |
| Stent implantation | 57 (86.4) | 69 (93.2) | 0.176 |
| Medications | |||
| Heparin | 53 (80.6) | 32 (42.6) | <0.001 |
| Statins | 46 (69.4) | 40 (54.4) | 0.067 |
| β blocker | 42 (63.9) | 58 (77.9) | 0.068 |
| IIb/IIIa inhibitor | 30 (45.5) | 43 (58.1) | 0.135 |
| Laboratory determinations | |||
| Serum Creatinine (µmol/L) | 97.5±24.0 | 96.9±26.0 | 0.871 |
| Platelet count (/L) | 222.1±101.5 | 216.4±76.5 | 0.708 |
| CK (U/L) | 431.3±900.6 | 357.5±905.9 | 0.63 |
Values were presented as number (%) and mean±SD. CK, creatine kinase.